MedTrace Logo

Canagliflozin in Patients With Acute Decompansted Heart Failure

NCT05364190 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2024-07-11

No results posted yet for this study

Summary

The study aims to investigate the efficacy and safety of the early initiation of canagliflozin treatment in hospitalized heart failure patients with volume overload (warm-wet) who require the use of I.V loop diuretic during the hospitalization period.

Conditions

Interventions

DRUG

Canagliflozin

Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.

DRUG

Empagliflozin

Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • National Heart Institute, Egypt

    collaborator OTHER_GOV

  • October 6 University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-04
Primary Completion
2023-12-01
Completion
2024-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364190 on ClinicalTrials.gov